Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rick Bangs

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|November 4, 2024
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder CancerParminder Singh, Leslie Ballas, Guru P Sonpavde, et al.
Clinical Genitourinary Cancer|November 7, 2022
Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources UniformlyAndrea Necchi, Monika Joshi, Rick Bangs, et al.
Urologic Oncology|October 7, 2023
Bladder cancer patient and provider perspectives on smoking cessationMatthew Mossanen, Angela B Smith, Nnamdi Onochie, et al.
BJU International|March 6, 2025
Understanding patient perspectives in the management of their muscle-invasive bladder cancerDeepro Chowdhury, Andrea B Apolo, Di Maria Jiang, et al.
Journal of the National Cancer Institute|January 4, 2024
Interventions addressing health-related social needs among patients with cancerEvan M Graboyes, Simon C Lee, Stacy Tessler Lindau, et al.
European Urology|August 18, 2023
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605Peter C Black, Catherine M Tangen, Parminder Singh, et al.
Cancer|March 5, 2013
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working GroupMatthew D Galsky, Ryan Hendricks, Robert Svatek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerSeth P Lerner, David J McConkey, Catherine M Tangen, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Bladder Cancer (Amsterdam, Netherlands)|November 4, 2024
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder CancerParminder Singh, Leslie Ballas, Guru P Sonpavde, et al.
Clinical Genitourinary Cancer|November 7, 2022
Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources UniformlyAndrea Necchi, Monika Joshi, Rick Bangs, et al.
Urologic Oncology|October 7, 2023
Bladder cancer patient and provider perspectives on smoking cessationMatthew Mossanen, Angela B Smith, Nnamdi Onochie, et al.
BJU International|March 6, 2025
Understanding patient perspectives in the management of their muscle-invasive bladder cancerDeepro Chowdhury, Andrea B Apolo, Di Maria Jiang, et al.
Journal of the National Cancer Institute|January 4, 2024
Interventions addressing health-related social needs among patients with cancerEvan M Graboyes, Simon C Lee, Stacy Tessler Lindau, et al.
European Urology|August 18, 2023
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605Peter C Black, Catherine M Tangen, Parminder Singh, et al.
Cancer|March 5, 2013
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working GroupMatthew D Galsky, Ryan Hendricks, Robert Svatek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerSeth P Lerner, David J McConkey, Catherine M Tangen, et al.
Pageof 4